Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODM-212
- Development stage
- Phase 2
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ODM-212 is an investigational oral small molecule drug developed by Orion for the treatment of advanced solid tumors. It functions as a TEA domain family member (TEAD) inhibitor, blocking TEAD activity within the Hippo signaling pathway, which is implicated in tumor growth and resistance mechanisms. ODM-212 specifically targets cancers with YAP/TEAD activation, including those with genetic alterations such as NF2 loss-of-function, LATS1/2 loss-of-function, or YAP/TAZ fusions. The drug is currently being evaluated in first-in-human clinical trials to assess its safety and efficacy in patients with locally advanced or metastatic solid tumors[1][3][4][6].
02
Targets
TEAD1TEAD3TEAD2 (TEA domain family member 2)TEAD4
Beyond the preview
Go deeper on ODM-212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODM-212.